Cisplatin dose reduction has different survival impact for human papillomavirus (HPV)-related (HPV+) and HPV-unrelated (HPV−) locally advanced head and neck cancer (LAHNC).
A survival benefit with cisplatin dose >200 mg/m2 is evident for HPV− LAHNC.
There was no significant survival difference in various cisplatin doses in HPV+ LAHNC overall.
There was a trend towards inferior survival with cisplatin ≤200 mg/m2 in HPV+ T4 or N3 subset.